Total debt of $743.6M against cash of $243.2M and negative shareholders' equity of -$54.2M in 2026Q3 suggests a strained capital structure in which obligations exceed total assets, even though the current ratio remains at 2.07.
Mirum Pharmaceuticals, Inc. (MIRM) balance sheet — 8-year assets, liabilities & shareholders' equity history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 |
|---|
| Total Current Assets | 586.63M | 549.68M | 392.79M | 387.54M | 190.22M | 166.59M | 236.35M | 119.36M | 51.98M |
| Cash & Short-Term Investments | 373.69M | 383.33M | 280.31M | 286.33M | 151.72M | 156.54M | 231.82M | 116.66M | 51.96M |
| Cash Only | 243.19M | 296.68M | 222.5M | 286.33M | 28M | 31.34M | 142.09M | 11.97M | 51.96M |
| Short-Term Investments | 130.5M | 86.64M | 57.81M | 0 | 123.72M | 125.2M | 89.73M | 104.69M | 0 |
| Accounts Receivable | 156.35M | 123.33M | 78.29M | 67.97M | 23.99M | 4.37M | 0 | 0 | 0 |
| Days Sales Outstanding | 75.93 | 86.35 | 84.82 | 133.11 | 113.65 | 83.29 | - | - | - |
| Inventory | 25.49M | 24.89M | 22.4M | 22.31M | 5.57M | 1.51M | 0 | 0 | 0 |
| Days Inventory Outstanding | 75.58 | 90.31 | 100.16 | 173.13 | 164.15 | 290.2 | - | - | - |
| Other Current Assets | 31.11M | 18.14M | 11.78M | 10.94M | 8.95M | 4.17M | 0 | 0 | 12K |
| Total Non-Current Assets | 439.98M | 293.13M | 277.97M | 259.08M | 162.68M | 128.06M | 4.51M | 27.35M | 0 |
| Property, Plant & Equipment | 14.61M | 10.6M | 9.81M | 1.99M | 2.35M | 2.55M | 3.24M | 3.73M | 0 |
| Fixed Asset Turnover | 49.19x | 49.17x | 34.33x | 93.66x | 32.86x | 7.51x | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 275.65M | 260.92M | 249.82M | 252.93M | 58.95M | 18.74M | 0 | 0 | 0 |
| Long-Term Investments | 292.26M | 8.11M | 12.53M | 0 | 0 | 4.98M | 0 | 23.29M | 0 |
| Other Non-Current Assets | 22.96M | 13.5M | 5.81M | 4.17M | 101.38M | 101.79M | 1.27M | 324K | 0 |
| Total Assets | 1.03B | 842.81M | 670.75M | 646.62M | 352.91M | 294.65M | 240.86M | 146.71M | 51.98M |
| Asset Turnover | 0.71x | 0.62x | 0.50x | 0.29x | 0.22x | 0.06x | - | - | - |
| Asset Growth % | 129.46% | 25.65% | 3.73% | 83.23% | 19.77% | 22.33% | 64.17% | 182.27% | - |
| Total Current Liabilities | 283.08M | 205.8M | 126.55M | 87.06M | 64.73M | 42.6M | 18.46M | 13.08M | 2.45M |
| Accounts Payable | 13.65M | 9.61M | 14.62M | 7.42M | 8.69M | 9.17M | 3.15M | 3.35M | 269K |
| Days Payables Outstanding | 78.87 | 34.89 | 65.35 | 57.54 | 256.33 | 1.76K | 1.85K | 3.78K | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 24.8M | 47.28M | 32.25M | 20.94M | 15.75M | 11.98M | 6.07M | 2.22M | 15K |
| Current Ratio | 2.07x | 2.67x | 3.10x | 4.45x | 2.94x | 3.91x | 12.80x | 9.13x | 21.22x |
| Quick Ratio | 1.98x | 2.55x | 2.93x | 4.19x | 2.85x | 3.88x | 12.80x | 9.13x | 21.22x |
| Cash Conversion Cycle | 72.64 | 141.77 | 119.62 | 248.7 | 21.47 | -1.38K | - | - | - |
| Total Non-Current Liabilities | 797.72M | 322.32M | 318.56M | 310.89M | 146.14M | 131.84M | 50.31M | 3.29M | 59.85M |
| Long-Term Debt | 731.25M | 309.8M | 308.08M | 306.42M | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 38.87M | 7.52M | 7.97M | 617K | 1.26M | 1.9M | 2.63M | 3.25M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 56.75M | 5.01M | 2.51M | 3.85M | 4.53M | 17K | 29K | 36K | 59.85M |
| Total Liabilities | 1.08B | 528.12M | 445.11M | 397.95M | 210.87M | 174.44M | 68.77M | 16.36M | 62.3M |
| Total Debt | 743.56M | 319.45M | 317.76M | 308.14M | 2.19M | 2.61M | 3.26M | 3.65M | 0 |
| Net Debt | 500.37M | 22.77M | 95.26M | 21.82M | -25.82M | -28.73M | -138.82M | -8.32M | -51.96M |
| Debt / Equity | -13.72x | 1.02x | 1.41x | 1.24x | 0.02x | 0.02x | 0.02x | 0.03x | - |
| Debt / EBITDA | -5.19x | 151.54x | - | - | - | - | - | - | - |
| Net Debt / EBITDA | -3.49x | 10.80x | - | - | - | - | - | - | -35.64x |
| Interest Coverage | -73.82x | -0.49x | -5.07x | -9.75x | -7.89x | -3.77x | -307.25x | - | - |
| Total Equity | -54.19M | 314.69M | 225.64M | 248.67M | 142.04M | 120.21M | 172.09M | 130.35M | -10.32M |
| Equity Growth % | -179.21% | 39.47% | -9.26% | 75.07% | 18.16% | -30.15% | 32.03% | 1362.7% | - |
| Book Value per Share | -0.82 | 6.27 | 4.75 | 6.08 | 4.18 | 3.96 | 6.82 | 5.67 | -0.45 |
| Total Shareholders' Equity | -54.19M | 314.69M | 225.64M | 248.67M | 142.04M | 120.21M | 172.09M | 130.35M | -10.32M |
| Common Stock | 7K | 5K | 5K | 5K | 4K | 3K | 3K | 2K | 6.99M |
| Retained Earnings | -1.57B | -667.54M | -644.18M | -556.24M | -392.82M | -257.16M | -173.17M | -69.9M | -17.35M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -2.06M | 351K | -373K | 1.64M | -217K | -35K | 83K | 129K | -66.84M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying MIRM stock.
As of 2025, Mirum Pharmaceuticals, Inc. (MIRM) had total assets of $842.8M including $549.7M in current assets.
Mirum Pharmaceuticals, Inc. (MIRM) carries total debt of $319.5M, offset by $383.3M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Mirum Pharmaceuticals, Inc. (MIRM) has total shareholders' equity (book value) of $314.7M ($6.27 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Mirum Pharmaceuticals, Inc. (MIRM) reported a current ratio of 2.67x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.
Key Metrics
Top Statement Risk
Deepening negative equity position
Metrics are mathematically derived from official filings.
Equity Deteriorating Toward Negative Territory
According to reported SEC filings, MIRM's shareholders' equity fell from $314.7M in 2025Q4 to negative $54.2M in 2026Q3, as total liabilities climbed to $1.1B against total assets of roughly $1.0B.
The swing from positive equity to a deficit suggests accumulated losses and possibly large non-operating charges are eroding the capital base faster than new capital is replacing it. Retained earnings of roughly negative $1.6B point to a long record of losses rather than a single event. Investors should monitor whether the company can restore positive equity before liabilities further outpace assets.
Leverage Rising Against a Shrinking Equity Base
Based on EDBL-style reported figures, MIRM's total debt of $743.6M in 2026Q3 is more than 2.3 times its cash of $243.2M, and the company's debt-to-equity ratio is no longer meaningful with equity now negative.
Total debt has roughly doubled from about $319M in 2025Q4 to $743.6M, indicating a material step-up in borrowing rather than gradual accumulation. Because the company now carries more liabilities than assets, the balance sheet offers little cushion if refinancing terms tighten. The reported figures warrant further investigation into the maturity profile and covenant terms of this debt.
Current Ratio Holds While Cash Thins
As reported in financial statements, MIRM's current ratio of 2.07 in 2026Q3 remains above 2.0, but cash fell from $330.7M in 2026Q2 to $243.2M, a decline of about 26% in one quarter.
A current ratio above 2.0 suggests short-term assets still exceed short-term obligations, though the quarterly cash decline points to continued burn. The cash position relative to ongoing operating costs appears to be narrowing, which may indicate a shortening runway. Liquidity conclusions depend on the composition of current assets, which the supplied data does not fully break out.
Goodwill Anchors Asset Base Growth
Based on reported figures, goodwill of $275.6M in 2026Q3 is a meaningful share of total assets near $1.0B, and it rose from about $260.9M in 2025Q4 alongside an expanding asset base.
Goodwill comprising roughly a quarter of total assets raises impairment risk if the acquired revenue streams underperform, a concern given the company's persistent operating losses. Net PP&E of only about $14.6M indicates an asset-light model where value rests mainly on intangibles and cash. The rising goodwill balance warrants monitoring alongside any acquisition activity disclosed in future filings.
Headline Liquidity Masks Equity Shortfall
As reported in the financial statements, the current ratio of 2.07 may appear comfortable, yet negative shareholders' equity of -$54.2M means the company's obligations exceed its total assets.
A healthy-looking current ratio can coexist with a broader solvency problem when long-term liabilities are large, and here total liabilities exceed total assets. Stock-based compensation reported in the cash flow analysis may also be softening the cash picture by paying a portion of costs in equity, which dilutes existing holders. Headline liquidity metrics alone may therefore understate the balance sheet strain.